Program

China, India, Brazil, Japan and Israel remain as some of the few bright spots during the global financial crisis. While VC investment in medtech and life science companies has slowed, medtech companies are demonstrating a healthy appetite for funding and launching novel, early stage technologies in these markets. Also with ambitious healthcare reforms and with the additional impact of driving down costs, these countries offer an attractive market to explore and exploit the opportunities. The panelists will share their personal experiences of working in emerging markets.

Moderator: Donald Coppen – Director, Partnering and Licensing, Biocompatibles UK

Panelists:

• Rajesh Dalal – Formerly Managing Director of J&J India and Chief of M&A for J&J Asia. Currently Independent Consultant for Medical Devices in India and China
• Huimin Wang – Corporate VP, Japan, Asia Pacific & Latin America, Edwards Lifesciences
• Menachem Zucker – VP Injectable Drug Delivery Devices, Elcam Medical

Ernst & Young will release half yearly updates to its second annual industry publication 'Pulse of the industry: Global medical technology report 2009', at EuroMedtech 2010. Key findings and trends will be shared and a distinguished panel of leading industry CEOs will share their insights and strategies on how their companies and others organizations can thrive having seen the green shoots of recovery in financial and commercial markets.

Moderator: Heinrich Christen – Partner and Industry Leader Medical Devices EMEIA, Ernst & Young

Panelists:

• Steven Dyson – Partner, Apax Partners
• Jason A. Hillenbach – Associate Director, Global Life Sciences Center, Ernst & Young
• Wolfgang Hofmann – Managing Director Pharma, Fresenius Medical Care and Chairman of the Board, ANM Adaptive Neuromodulation
• Rob de Ree – CEO, BMEYE
• Roger Stadler – Managing Director, icotec

With revisions to the EU medical device directive in March 2010, this will be an opportunity to check with authorities and notified bodies that you are fully complying. The panel will also discuss the very latest updates to the reimbursement and pricing system from EU healthcare agencies, and industry experts will share their experiences and success stories on how to gain or maintain market share and achieve reimbursement as early as possible.

Moderator: Hubertus Rosery – CEO, AiM

Panelists:

• Brigitte Casteels-Rappagliosi – Director Health Policy, Pricing and Public Affairs, Stryker Europe
• Fabien Roy – EU Regulatory Affairs Advisor, Hogan Lovells
• Harry van Vugt – Senior Project Manager, Certification Manager, KEMA Quality

The European Commission back in 2007 reported on lead market opportunities for eHealth and proposed actions aiming to accelerate and develop the European eHealth market, increasing economic benefits and simultaneously developing the quality of health products and services. The recommendations highlighted the focus on dealing with identified obstacles: reducing market fragmentation and interoperability; improving legal certainty and consumer acceptance; facilitating access to funding; and improving procurement activities. Leaders and stakeholders in this field will discuss the growing demand and market growth opportunities and the structural barriers delaying successful market breakthrough.

Moderator: Uwe Buddrus – CEO, Data Information Intelligence

Panelists:

• Felix Brand – CEO, Personal MedSystems
• Klaus Juffernbruch – Director, Connected Health Internet Business Solutions, Cisco Systems
• Richard Rees Davies– General Manager, Home Health, GE Healthcare UK & Ireland
  
• Jens Seeliger – Strategic Relations Manager, Intel Digital Health Group

The panel will review the focus on strategies and pivotal tactics for commercialization of regenerative medicine and novel products, building on the successes of advances in orthopedics, wound healing, stem cells and other cellular therapies. What is really ground breaking with the mix of biological and new materials and can these be cultivated into sustainable products and businesses?

Moderator: Timothy J. Haines – Partner, Abingworth Management

Panelists:

• Gil Beyen – CEO, TiGenix
• Paul Borm – CSO, MagnaMedics
• Ian Brown – CEO, RepRegen
• Leanna M. Caron – VP and General Manager, Cell Therapy and Regenerative Medicine, Genzyme BioSurgery

Bringing medtech products to the US marketplace requires a thorough understanding of how customers make buying decisions in the unique reimbursement and insurance environment, product liability issues, regulatory requirements, the regulatory process, cultural issues, and an adequate timeframe for ultimate success. This workshop will provide a roadmap for successfully entering the US marketplace, including:

• Market demographics and projections
• Selecting the best entry strategy
• Working with key opinion leaders
• Establishing sales and distribution channels
• Navigating rapid regulatory approval
• Realistic sales projections and expenses
• Reimbursement

This workshop will specifically look at the current downturn and how this may affect the thinking of launching in the largest medical device market in the world.

Moderator: Reinhard Merz – Director European Operations, TCG

Panelists:

• Robert Keefer – Partner, TCG
• Albrecht Windelband – CEO, Abtswinder Naturheilmittel

With the backdrop of global economic difficulties, medtech companies have seen their share of trying times. What is the view for investment and dealmaking for the year ahead? The panel will also address stimulus funding and exit strategies.

Moderator: Olivier Litzka – Partner, Edmond de Rothschild Investment Partners

Panelists:

• Nissim Darvish – Senior Managing Director, OrbiMed Israel
• Antoine Papiernik – Managing Partner, Sofinnova Partners
• Michael Simpson – CEO, Knee Creations
• Helmut J. Straubinger – CEO, JenaValve

As we ring in a new decade, we reflect on how far we have come—from new healthcare reform and containment of medical expenses to technological and medical advances. We now have a strong consensus in favor of personal wellness. The benefits—for consumers, healthcare professionals, employers, and taxpayers—are considerable. What will these changes in policy and practice mean for us down the road, and how will healthcare evolve in the coming years in terms of the greater emphasis on prevention, screening, early diagnosis and use of IVDs?

Moderator: Ashley Yeo – Principal Analyst, Informa

Panelists:

• Alan Davies – CMO EMEA, GE Healthcare
• Janke Dittmer – Senior Director, Head of Business Development and Strategy, Philips Healthcare Incubator
• Martin Huber – Corporate Technology, Siemens and THESEUS Forschungsprogramm
• Olaf Wilhelm – CEO, Wilex

Navigating the complicated waters of current diagnosis, investigation, and managing patients with cardiovascular disease, with the development requirements for devices for interventional cardiology, we need a thorough understanding of the competitive landscape. What strategies should investors and companies be developing around these opportunities? What are the specific interventional cardiology devices to develop and what are the regulatory pitfalls to consider? How will commercialization and IP affect the M&A landscape?

Moderator: Marion Jung – Principal, Earlybird Venture Capital

Panelists:

• Peter E. Albrecht – Managing Director, Boston Scientific Technologie Zentrum
• Eric Le Royer – CEO, Endosense
• Stefan Thamasett – General Manager, Berlin Heart